Global Microbiome Partnering Terms and Agreements 2014-2019: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com

DUBLIN--()--The "Global Microbiome Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Microbiome Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Report scope

  • Trends in Microbiome dealmaking in the biopharma industry since 2014
  • Analysis of Microbiome deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Microbiome deals
  • Access to over 130 Microbiome deal records and contract documents where available
  • The leading antibody deals by value since 2014
  • Most active Microbiome dealmakers since 2014
  • The leading Microbiome partnering resources

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Microbiome dealmaking

2.1. Introduction

2.2. Microbiome partnering over the years

2.3. Most active Microbiome dealmakers

2.4. Microbiome partnering by deal type

2.5. Microbiome partnering by therapy area

2.6. Microbiome partnering by industry sector

2.7. Deal terms for Microbiome partnering

2.7.1 Microbiome partnering headline values

2.7.2 Microbiome deal upfront payments

2.7.3 Microbiome deal milestone payments

2.7.4 Microbiome royalty rates

2.8. The anatomy of an Microbiome deal

2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals

2.8.b. Case study 2: Hospira & Cempra Pharmaceutical

2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Microbiome deals

3.1. Introduction

3.2. Top Microbiome deals by value

Chapter 4 - Most active Microbiome dealmakers

4.1. Introduction

4.2. Most active Microbiome dealmakers

4.3. Most active Microbiome partnering company profiles

Chapter 5 - Microbiome contracts dealmaking directory

5.1. Introduction

5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Microbiome deals by company A-Z

Appendix 2 - Microbiome deals by stage of development

Appendix 3 - Microbiome deals by deal type

Appendix 4 - Microbiome deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/st4acs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals